Anti-microbial resistant in Gram-negative bacteria bacillus: Enterobacteriaceae and non-fermenting bacilli isolated at Sominé DOLO Hospital of Mopti, Mali
Background: β-lactams and carbapenems. are the major antibiotics used to treat gram-negative bacteria and non-fermenting bacilli. However, the increasing production of β-lactamase and carbapenemase limits the therapeutic options. Our study aims to determine the resistant phenotypes of these bacteria while describing their epidemiological aspect. Material and Methods: This was a cross-sectional study by consecutive enrollment from January 2018 to December 2019 at Sominé DOLO Hospital of Mopti, Mali. We performed manual method for bacteria culture, identification and antibiotics sensitivity testing. The antibiotics sensitivity testing was accessed by the diffusion method according to CA-SFM/EUCAST (“Comité de l’Antibiogramme de la Société Française de Microbiologie” / European Committee on Antimicrobial Susceptibility Testing) recommendations V1.0 february 2018 and V2.0 may 2019 2019 V.2.0. May recommendation released in 2019. Data were analyzed by software R 4.0.3 GUI 1.73 Catalina build (7892). Results: At all 904 samples were included in this study. Out of the 904 cultures, 297 sample (32.85%) were positive. The rates of enzymes production were as follow: Extended-spectrum ß-lactamase (ESBL) 56.42% (101/179), cepholosporinase hyperproduction (HCASE) 15.64% (28/179), cephalosporinase production (CASE) 6.14% (11/179), penicillinase hyperproduction (HP) 5.58% (10/179), carbapenemase production (CP) 6.14% (11/179) and savage strains 10.05% (18/179). Conclusion: Our data showed a high prevalence of resistance to β-lactamins ß-talactamins and carbapenemes in gram-negative bacteria and non-fermenting bacillus bacilli. The A high level of β-lactamase and carbapenemase production by gram negative bacillus were also reported by others authors calls for the rational use of antibiotic in hospital setting.